EP4709730A1 - Composés hétéroaryle en tant qu'agents de dégradation dirigés contre un ligand ciblant irak4 - Google Patents

Composés hétéroaryle en tant qu'agents de dégradation dirigés contre un ligand ciblant irak4

Info

Publication number
EP4709730A1
EP4709730A1 EP24740633.3A EP24740633A EP4709730A1 EP 4709730 A1 EP4709730 A1 EP 4709730A1 EP 24740633 A EP24740633 A EP 24740633A EP 4709730 A1 EP4709730 A1 EP 4709730A1
Authority
EP
European Patent Office
Prior art keywords
mmol
compound
pharmaceutically acceptable
acceptable salt
dmso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24740633.3A
Other languages
German (de)
English (en)
Inventor
Geraint Davies
Paul E. GORMISKY
Timothy Gordon RASMUSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of EP4709730A1 publication Critical patent/EP4709730A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés et des compositions de ceux-ci pour moduler IRAK4. Dans certains modes de réalisation, les composés et les compositions sont fournis pour le traitement de maladies inflammatoires ou auto-immunes.
EP24740633.3A 2023-05-11 2024-05-09 Composés hétéroaryle en tant qu'agents de dégradation dirigés contre un ligand ciblant irak4 Pending EP4709730A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363465602P 2023-05-11 2023-05-11
PCT/US2024/028512 WO2024233742A1 (fr) 2023-05-11 2024-05-09 Composés hétéroaryle en tant qu'agents de dégradation dirigés contre un ligand ciblant irak4

Publications (1)

Publication Number Publication Date
EP4709730A1 true EP4709730A1 (fr) 2026-03-18

Family

ID=91898185

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24740633.3A Pending EP4709730A1 (fr) 2023-05-11 2024-05-09 Composés hétéroaryle en tant qu'agents de dégradation dirigés contre un ligand ciblant irak4

Country Status (4)

Country Link
EP (1) EP4709730A1 (fr)
KR (1) KR20260010406A (fr)
CN (1) CN121152790A (fr)
WO (1) WO2024233742A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025149070A1 (fr) * 2024-01-10 2025-07-17 甘李药业股份有限公司 Synthèse et utilisation d'un nouveau composé chimère de protéolyse ciblant la kinase 4 associée au récepteur de l'interleukine-1 (irak4)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3267996B1 (fr) * 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité d'irak4 à base de pyrazolopyrimidine
CA3229646A1 (fr) * 2021-08-23 2023-03-02 Zhengqing YE Agent de degradation d'irak4, son procede de preparation et son utilisation
EP4472967A4 (fr) * 2022-01-31 2026-04-15 Kymera Therapeutics Inc Agents de dégradation d'irak et leurs utilisations
CN119894895A (zh) * 2022-11-04 2025-04-25 领泰生物医药(绍兴)有限公司 Irak4降解剂及其用途

Also Published As

Publication number Publication date
KR20260010406A (ko) 2026-01-20
WO2024233742A1 (fr) 2024-11-14
CN121152790A (zh) 2025-12-16

Similar Documents

Publication Publication Date Title
US10947213B1 (en) TLR7/8 antagonists and uses thereof
IL305262A (en) Small molecule inhibitors of mammalian SLC6A19 function
KR20250172881A (ko) 글루코스-의존성 인슐린 분비 촉진 폴리펩티드 수용체 길항제 및 이의 용도
TWI872177B (zh) 對核受體具有活性之化合物
CA3182325A1 (fr) Composes de liaison au cereblon, compositions de ceux-ci et procedes de traitement avec ceux-ci
US11447479B2 (en) Compounds active towards nuclear receptors
WO2024233742A1 (fr) Composés hétéroaryle en tant qu'agents de dégradation dirigés contre un ligand ciblant irak4
WO2024026256A1 (fr) Composés d'imidazopyrazine substitués en tant qu'agents de dégradation d'irak3 dirigés contre le ligand
EP4709486A1 (fr) Composés hétéroaryle en tant qu'agents de dégradation dirigés contre un ligand d'irak4
EP4709389A1 (fr) Composés hétéroaryle en tant qu'agents de dégradation dirigés contre un ligand ciblant irak4
CA3160508C (fr) Composes de ((((6-benzylamino-5-fluoropyrimidine-4-yl)amino)methyle)-piperidine-1-yl)acetamide substitues actifs a l'endroit des recepteurs nucleaires
KR102959787B1 (ko) 핵 수용체 활성 화합물
US11780843B2 (en) Compounds active towards nuclear receptors
EP4638454A1 (fr) Composés substitués à base d'imidazo en tant qu'agents de dégradation dirigés contre un ligand d'irak3
EP3793996A1 (fr) Inhibiteurs de kinases
WO2025151602A1 (fr) Composés hétéroaryles utilisés en tant qu'agents de dégradation d'irak4 dirigés contre un ligand
US20250197374A1 (en) Wee1 degrading compounds and uses thereof
WO2024026262A1 (fr) Composés pyrazolyl-pyridinyle substitués utilisés comme agents de dégradation d'irak3 dirigés contre le ligand
WO2026059895A1 (fr) Dérivés de tricyclohétérocyclylsulfonamide substitués et leurs utilisations
US20250100995A1 (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
EA047629B1 (ru) Соединения, активные в отношении ядерных рецепторов
US20220098182A1 (en) Compounds active towards nuclear receptors
HK40077526B (zh) 对核受体具有活性的化合物

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251209

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR